A study of safety and efficacy of ipragliflozin in the treatment of diabetes in Kanagawa
Phase of Trial: Phase IV
Latest Information Update: 03 Sep 2018
Price : $35 *
At a glance
- Drugs Ipragliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms ASSIGN-K
- 27 Aug 2018 Status changed from active, no longer recruiting to completed.
- 08 Mar 2017 Status changed from recruiting to active, no longer recruiting.
- 15 Aug 2014 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan